over a seven year period from 1982 to 1989,3337 conduits were created in 3137 patients with end stage renal disease (esrd) as access for chronic dialysis. these included 2690 side-to-side arteriovenous fistulae (a vf), 168 end-to-side a vfs, 10 autogenous vein grafts, 51 homogenous frozen vein grafts, 109 polytetrafluoroethylene (ptfe) grafts, 209 emergency external arteriovenous shunts, three ...

OBJECTIVE Intraosseous access (IO) is becoming increasingly accepted in adult populations as an alternative to peripheral vascular access; however, there is still insufficient evidence in large patient groups supporting its use. METHODS Retrospective review. This paper reports on the use of IO devices over a 7-year period from August 2006 to August 2013 during combat operations in Afghanistan...

BACKGROUND We evaluated the long term clinical outcomes of femoral vascular closure devices following its deployment in coronary angiography and percutaneous coronary intervention (PCI) procedures. METHODS From June 2000 to September 2004, 265 patients who received femoral vascular closure devices after coronary angiography and PCIs were enrolled into the study. Patients' medical records were...

Radial access combined with hemodynamic support has the limitation of not allowing adequate angiography or delivery peripheral balloons for managing femoral site after removal large sheath. We present a case series use novel long 6 French guiding sheath via left radial artery ventricular assist device vascular closure devices.

Understanding the needs of the patients, dialysis staff, and nephrologists is the first logical step in the technological development of better haemodialysis devices. This includes the understanding of large and small uraemic toxins and their removal by dialysis membranes, pathophysiology of intradialytic symptomatology, and problems associated with vascular access. Each of these areas can bene...

Thousands of critically ill emergency patients are treated in the out-of-hospital setting in the United States every year. In many patients intravenous (IV) therapy cannot be initiated because of inadequate access to peripheral veins. In some cases, this lack of vascular access may limit benefit of medications because of late administration.[1] Both speed and overall success of vascular access ...